Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...
LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results